Only tucatinib [18], lapatinib, and neratinib were investigated in future reports and showed excellent response charges and response period. From the HER2CLIMB trial the secondary endpoint of PFS in patients with brain metastases showed a major reduction in the chance of progression or Demise by 52% while in the tucatinib arm. From the presence o